June 19, 2026
Eumar Technology acquires R&D-leader Hybrisan to advance wound care innovation and UK manufacturing
Hereford, England and Port Talbot, South Wales – 19 June 2026
Leading specialist wound care manufacturer Eumar Technology Limited has acquired Universal Synergistic Holdings Limited, trading as Hybrisan, creating one of the UK’s most exciting new CDMOs in the sector.
This acquisition strengthens Eumar Technology’s medical device development and manufacturing capabilities and furthers its ambition to establish itself as a leading UK-based contract development and manufacturing organisation (CDMO).
This move establishes a clearly defined and complementary structure, combining Eumar Technology’s ISO 13485-certified manufacturing facilities and superabsorbent materials expertise with Hybrisan’s product development expertise in electrospinning and antimicrobials. Additionally, Eumar Technology’s diversification strategy of its technology portfolio will de-risk its business and use that strength to allow the Hereford-based company to offer increased value to existing customers.
Hybrisan, founded in 2013, has built a strong reputation in chronic wound care. Its lead product, WoundSan®, is a clinically evidenced wound cleansing technology currently progressing through EU MDR approval and expected to reach the market later this year. Hybrisan will continue to operate from its headquarters in Port Talbot, with increased investment from its new owners in its South Wales innovation hub.
Chronic, hard-to-heal wounds represent a significant and growing challenge for healthcare systems. The global advanced wound care market has experienced high levels of growth in recent years and was valued at over $20 billion in 2025. This acquisition positions the combined business to develop and commercialise advanced wound care solutions that improve patient outcomes and support more efficient care pathways.
Chris Mortimer, Chief Technology Officer (formerly CEO, Hybrisan): “Combining Hybrisan’s development expertise with Eumar’s manufacturing capability, infrastructure and commercial reach will allow us to accelerate innovative wound care solutions to market. The continuation of operations in Port Talbot ensures the specialist skills we have built in South Wales remain central to the group’s future.”
Geraldine Johnson, Managing Director, Eumar Technology: “Hybrisan is an excellent strategic fit. Its technical capabilities, intellectual property and innovation pipeline significantly enhance our ability to support customers across the full product lifecycle – from concept and development through to regulatory approval and commercial manufacture.”
Euan Davidson, Chairman, Eumar Technology: “This is Eumar’s first ever acquisition and we are very excited to bring the extensive expertise and product pipeline of Hybrisan into our group. We are committed to being at the forefront of development and manufacturing of world class medical devices from here in the UK.
This acquisition is central to our long-term strategy to build a leading UK medical device business. We are committed to investing in skilled employment and manufacturing excellence across both Herefordshire and South Wales, with the goal of creating a CDMO recognised internationally for taking innovative products from concept to commercial manufacture entirely within the United Kingdom.”
Terms of the acquisition will remain commercially confidential.
